GSK submitted to the EU for new indications Votrient
GlaxoSmithKline (GSK) today announced that it has European Medicines Agency (EMA) has submitted Votrient (pazopanib) application for a new indication will votrient condition for receiving first-line chemotherapy did not worsen the II-IV stage ovarian cancer, fallopian tube cancer, primary peritoneal cancer patients maintenance therapy.
This application is votrient less than five years in the EU presented the first three indications
GSK submitted to the EU for new indications Votrient
ReplyDeleteGlaxoSmithKline (GSK) today announced that it has European Medicines Agency (EMA) has submitted Votrient (pazopanib) application for a new indication will votrient condition for receiving first-line chemotherapy did not worsen the II-IV stage ovarian cancer, fallopian tube cancer, primary peritoneal cancer patients maintenance therapy.
This application is votrient less than five years in the EU presented the first three indications
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
Ruxolitinib phosphate
INCB018424 sulfate
Baricitinib
AZD-1480
TG-101348
TG101209
CYT387
LY2784544
Baricitinib
WHI-P97